Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

MyNCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1964 1
1965 6
1966 8
1967 7
1968 8
1969 20
1970 9
1971 16
1972 12
1973 14
1974 21
1975 21
1976 19
1977 20
1978 20
1979 27
1980 25
1981 25
1982 20
1983 39
1984 38
1985 32
1986 37
1987 36
1988 63
1989 42
1990 46
1991 50
1992 50
1993 54
1994 48
1995 62
1996 59
1997 70
1998 63
1999 66
2000 59
2001 67
2002 69
2003 93
2004 98
2005 118
2006 110
2007 143
2008 149
2009 151
2010 158
2011 188
2012 223
2013 251
2014 244
2015 265
2016 255
2017 270
2018 236
2019 78
2020 0
Text availability
Article attribute
Article type
Publication date

Search Results

3,973 results
Results by year
Filters applied: . Clear all
Page 1
Pulmonary vascular remodeling in pulmonary hypertension.
Tuder RM. Cell Tissue Res 2017 - Review. PMID 28025704 Free PMC article.
Pulmonary vascular remodeling is the key structural alteration in pulmonary hypertension and involves changes in the intima, media and adventitia, often with the interplay of inflammatory cells. ...
Pulmonary vascular remodeling is the key structural alteration in pulmonary hypertension and involves changes in the intima, media an …
Mechanisms of disease: pulmonary arterial hypertension.
Schermuly RT, et al. Nat Rev Cardiol 2011 - Review. PMID 21691314
Our understanding of, and approach to, pulmonary arterial hypertension has undergone a paradigm shift in the past decade. Once a condition thought to be dominated by increased vasoconstrictor tone and thrombosis, pulmonary arterial hypertension is now seen as a vasculopathy in which structural changes driven by excessive vascular cell growth and inflammation, with recruitment and infiltration of circulating cells, play a major role. ...Elucidating their contribution to the pathophysiology of pulmonary arterial hypertension could offer new drug targets. The role of progenitor cells in vascular repair is also under active investigation. ...
Our understanding of, and approach to, pulmonary arterial hypertension has undergone a paradigm shift in the past decade. Once a cond …
GPCRs in pulmonary arterial hypertension: tipping the balance.
Iyinikkel J and Murray F. Br J Pharmacol 2018 - Review. PMID 29468655 Free PMC article.
Pulmonary arterial hypertension (PAH) is a progressive, fatal disease characterised by increased pulmonary vascular resistance and excessive proliferation of pulmonary artery smooth muscle cells (PASMC). ...
Pulmonary arterial hypertension (PAH) is a progressive, fatal disease characterised by increased pulmonary vascular resistance and ex …
Pulmonary hypertension in patients with interstitial lung disease.
Karampitsakos T, et al. Pulm Pharmacol Ther 2018 - Review. PMID 29605286
This multidisciplinary approach involves the assessment of comorbid conditions including pulmonary hypertension (PH) that exerts a dramatic impact on survival. ...
This multidisciplinary approach involves the assessment of comorbid conditions including pulmonary hypertension (PH) that exerts a dr …
Pulmonary hypertension.
Mise J. Jpn Circ J 1974 - Review. PMID 4612185
Pulmonary arterial hypertension and the potential roles of metallothioneins: A focused review.
Maarman GJ. Life Sci 2018 - Review. PMID 30355531
The pathophysiology of pulmonary arterial hypertension (PAH) is underlined by cell proliferation and vasoconstriction of pulmonary arterioles this involves multiple molecular factors or proteins, but it is not clear what the exact roles of these factors/proteins are. ...
The pathophysiology of pulmonary arterial hypertension (PAH) is underlined by cell proliferation and vasoconstriction of pulmonary ar …
[Pulmonary hypertension - disease mechanisms].
Helán M, et al. Vnitr Lek 2014 - Review. PMID 25382008 Czech.
Pulmonary hypertension (PH) is known for its variable etiology. PH pathophysiology is very complex and our therapeutic options are limited. ...This review aims to summarize and explain the nature of the functional and histological changes in pulmonary arteries which occur in pulmonary hypertension, separately define the role of endothelium and pulmonary artery myocytes, and discuss the most important known pathophysiological mechanisms that lead to these changes....
Pulmonary hypertension (PH) is known for its variable etiology. PH pathophysiology is very complex and our therapeutic options are li …
Borderline pulmonary hypertension associated with chronic hypercapnia in chronic pulmonary disease.
Zuoyou L, et al. Respir Physiol Neurobiol 2019. PMID 30660859
Pulmonary hypertension (PH) due to lung diseases is classified as group 3 by the Dana Point classification. Given the basic pathophysiological conditions of group 3 lung diseases and the previously well-known concept of hypercapnic pulmonary vasoconstriction, chronic hypercapnia besides alveolar hypoxia might be another causative factor to increase mean pulmonary arterial pressure (PAm). ...
Pulmonary hypertension (PH) due to lung diseases is classified as group 3 by the Dana Point classification. Given the basic pathophys …
3,973 results
Jump to page
Feedback